scPharmaceuticals (SCPH) Stock Price, News & Analysis

Company Overview

scPharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on developing innovative therapies for sickle cell disease. The company’s lead product candidate, SC411, is an investigational intravenous formulation of a hemoglobin polymerization inhibitor designed to rapidly increase hemoglobin oxygen affinity and potentially reduce the severity and duration of vaso‐occlusive crises. By delivering a water‐soluble prodrug directly into the bloodstream, scPharmaceuticals aims to address an acute unmet need in emergency and inpatient settings where swift intervention can improve patient outcomes.

In addition to SC411, scPharmaceuticals is advancing a pipeline of small‐molecule candidates that target different aspects of red blood cell pathology in sickle cell disease. The company’s research and development efforts leverage proprietary prodrug technology to enhance delivery and bioavailability, with the goal of providing both acute crisis interventions and chronic disease management options. scPharmaceuticals collaborates with academic institutions and clinical research organizations to conduct Phase 1 studies and plans to initiate later‐stage trials upon successful completion of early safety and pharmacokinetic assessments.

Headquartered in Cambridge, Massachusetts, scPharmaceuticals was founded to translate cutting‐edge science into practical treatments for patients suffering from sickle cell disease. The company’s leadership team comprises industry veterans with experience in hematology, drug development and regulatory affairs. While initially focused on the U.S. market, scPharmaceuticals has stated its intention to expand clinical programs internationally as it progresses toward potential product approvals.

Key Stats

• Today's Range: $5.67 to $5.67
• 50-Day Range: $5.50 to $5.75
• 52-Week Range: $2.20 to $6.28
• Volume: N/A
• Average Volume: 953,834 shs
• Market Capitalization: $302.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.68
• Consensus Rating: Reduce

scPharmaceuticals Stock Analysis - MarketRank™

scPharmaceuticals scored higher than 3% of companies evaluated by MarketBeat, and ranked 847th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.9 / 5
• Analyst Rating: Reduce

Consensus Rating

scPharmaceuticals has received a consensus rating of Reduce. The company's average rating score is 1.75, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for scPharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

scPharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for scPharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of scPharmaceuticals is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of scPharmaceuticals is -3.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

scPharmaceuticals has a P/B Ratio of 21.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SCPH.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

scPharmaceuticals does not currently pay a dividend.

Dividend Growth

scPharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for scPharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, scPharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.78% of the stock of scPharmaceuticals is held by insiders.

Percentage Held by Institutions

89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2025
• Today: 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCPH
• CIK: 1604950
• Web: www.scpharma.com
• Phone: (617) 517-0730
• Fax: N/A
• Employees: 30
• Year Founded: 2014

Price Target and Rating

• Average Price Target for scPharmaceuticals: $5.68
• High Price Target: $6.00
• Low Price Target: $5.35
• Potential Upside/Downside: +0.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.75
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$85.15 million
• Net Margins: -183.55%
• Pretax Margin: -183.55%
• Return on Equity: -1,647.86%
• Return on Assets: -71.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.85
• Quick Ratio: 3.14

Sales & Book Value

• Annual Sales: $49.97 million
• Price / Sales: 6.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 21.00

Miscellaneous

• Outstanding Shares: 53,298,000
• Free Float: 50,750,000
• Market Cap: $302.20 million
• Optionable: Optionable
• Beta: 0.31